Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma

Tatsuro Tajiri, Shinji Tanaka, Kumiko Shono, Yoshiaki Kinoshita, Yoshimitu Fujii, Sachiyo Suita, Kenji Ihara, Toshiro Hara

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The amplification of the N-myc gene and a gain of the chromosome 17q arm correlate with an unfavorable outcome in patients with neuroblastoma. In this study, we determined the gene dosage of the N-myc gene (located at 2p24) and Survivin gene (located at 17q25) using the p53 gene (located at 17p13) as the internal control gene by the TaqMan polymerase chain reaction (PCR)-based gene dosage analysis in 25 neuroblastoma samples. Based on the assumption that the gene dosages of each gene of a normal individual lymphocytes are 1.0, 11 of the 25 cases with a corrected gene dosage of N-myc (N-myc/p53) of more than 2.0 had a more unfavorable prognosis than the 14 cases with a N-myc gene dosage of less than 2.0 (5-year survival rate: 18 vs. 71%, P < 0.01). Ten of 25 cases with a corrected Survivin gene dosage (Survivin/p53) of more than 2.0 had a more unfavorable prognosis than the 15 cases with a Survivin gene dosage of less than 2.0 (5-year survival rate: 10 vs. 67%, P < 0.01). This quantitative PCR system is considered to be useful for quickly and accurately evaluating the degree of malignancy of neuroblastoma in order to select the optimal treatment.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalCancer Letters
Volume166
Issue number1
DOIs
Publication statusPublished - May 10 2001

Fingerprint

Gene Dosage
Neuroblastoma
myc Genes
Survival Rate
Genes
Polymerase Chain Reaction
p53 Genes
Chromosomes
Lymphocytes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tajiri, T., Tanaka, S., Shono, K., Kinoshita, Y., Fujii, Y., Suita, S., ... Hara, T. (2001). Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Letters, 166(1), 89-94. https://doi.org/10.1016/S0304-3835(01)00434-7

Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. / Tajiri, Tatsuro; Tanaka, Shinji; Shono, Kumiko; Kinoshita, Yoshiaki; Fujii, Yoshimitu; Suita, Sachiyo; Ihara, Kenji; Hara, Toshiro.

In: Cancer Letters, Vol. 166, No. 1, 10.05.2001, p. 89-94.

Research output: Contribution to journalArticle

Tajiri, T, Tanaka, S, Shono, K, Kinoshita, Y, Fujii, Y, Suita, S, Ihara, K & Hara, T 2001, 'Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma', Cancer Letters, vol. 166, no. 1, pp. 89-94. https://doi.org/10.1016/S0304-3835(01)00434-7
Tajiri, Tatsuro ; Tanaka, Shinji ; Shono, Kumiko ; Kinoshita, Yoshiaki ; Fujii, Yoshimitu ; Suita, Sachiyo ; Ihara, Kenji ; Hara, Toshiro. / Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. In: Cancer Letters. 2001 ; Vol. 166, No. 1. pp. 89-94.
@article{ae1ef6dafe2440d3a121f4173b97678d,
title = "Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma",
abstract = "The amplification of the N-myc gene and a gain of the chromosome 17q arm correlate with an unfavorable outcome in patients with neuroblastoma. In this study, we determined the gene dosage of the N-myc gene (located at 2p24) and Survivin gene (located at 17q25) using the p53 gene (located at 17p13) as the internal control gene by the TaqMan polymerase chain reaction (PCR)-based gene dosage analysis in 25 neuroblastoma samples. Based on the assumption that the gene dosages of each gene of a normal individual lymphocytes are 1.0, 11 of the 25 cases with a corrected gene dosage of N-myc (N-myc/p53) of more than 2.0 had a more unfavorable prognosis than the 14 cases with a N-myc gene dosage of less than 2.0 (5-year survival rate: 18 vs. 71{\%}, P < 0.01). Ten of 25 cases with a corrected Survivin gene dosage (Survivin/p53) of more than 2.0 had a more unfavorable prognosis than the 15 cases with a Survivin gene dosage of less than 2.0 (5-year survival rate: 10 vs. 67{\%}, P < 0.01). This quantitative PCR system is considered to be useful for quickly and accurately evaluating the degree of malignancy of neuroblastoma in order to select the optimal treatment.",
author = "Tatsuro Tajiri and Shinji Tanaka and Kumiko Shono and Yoshiaki Kinoshita and Yoshimitu Fujii and Sachiyo Suita and Kenji Ihara and Toshiro Hara",
year = "2001",
month = "5",
day = "10",
doi = "10.1016/S0304-3835(01)00434-7",
language = "English",
volume = "166",
pages = "89--94",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma

AU - Tajiri, Tatsuro

AU - Tanaka, Shinji

AU - Shono, Kumiko

AU - Kinoshita, Yoshiaki

AU - Fujii, Yoshimitu

AU - Suita, Sachiyo

AU - Ihara, Kenji

AU - Hara, Toshiro

PY - 2001/5/10

Y1 - 2001/5/10

N2 - The amplification of the N-myc gene and a gain of the chromosome 17q arm correlate with an unfavorable outcome in patients with neuroblastoma. In this study, we determined the gene dosage of the N-myc gene (located at 2p24) and Survivin gene (located at 17q25) using the p53 gene (located at 17p13) as the internal control gene by the TaqMan polymerase chain reaction (PCR)-based gene dosage analysis in 25 neuroblastoma samples. Based on the assumption that the gene dosages of each gene of a normal individual lymphocytes are 1.0, 11 of the 25 cases with a corrected gene dosage of N-myc (N-myc/p53) of more than 2.0 had a more unfavorable prognosis than the 14 cases with a N-myc gene dosage of less than 2.0 (5-year survival rate: 18 vs. 71%, P < 0.01). Ten of 25 cases with a corrected Survivin gene dosage (Survivin/p53) of more than 2.0 had a more unfavorable prognosis than the 15 cases with a Survivin gene dosage of less than 2.0 (5-year survival rate: 10 vs. 67%, P < 0.01). This quantitative PCR system is considered to be useful for quickly and accurately evaluating the degree of malignancy of neuroblastoma in order to select the optimal treatment.

AB - The amplification of the N-myc gene and a gain of the chromosome 17q arm correlate with an unfavorable outcome in patients with neuroblastoma. In this study, we determined the gene dosage of the N-myc gene (located at 2p24) and Survivin gene (located at 17q25) using the p53 gene (located at 17p13) as the internal control gene by the TaqMan polymerase chain reaction (PCR)-based gene dosage analysis in 25 neuroblastoma samples. Based on the assumption that the gene dosages of each gene of a normal individual lymphocytes are 1.0, 11 of the 25 cases with a corrected gene dosage of N-myc (N-myc/p53) of more than 2.0 had a more unfavorable prognosis than the 14 cases with a N-myc gene dosage of less than 2.0 (5-year survival rate: 18 vs. 71%, P < 0.01). Ten of 25 cases with a corrected Survivin gene dosage (Survivin/p53) of more than 2.0 had a more unfavorable prognosis than the 15 cases with a Survivin gene dosage of less than 2.0 (5-year survival rate: 10 vs. 67%, P < 0.01). This quantitative PCR system is considered to be useful for quickly and accurately evaluating the degree of malignancy of neuroblastoma in order to select the optimal treatment.

UR - http://www.scopus.com/inward/record.url?scp=0035837654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035837654&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(01)00434-7

DO - 10.1016/S0304-3835(01)00434-7

M3 - Article

C2 - 11295291

AN - SCOPUS:0035837654

VL - 166

SP - 89

EP - 94

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -